Platinum Industries Ltd
PLATINDPlatinum Industries Ltd's earnings have outrun its stock. EPS grew +4.3% in a year against a −18.2% price move.
The sharpest disagreement: profits are rising, but only 17% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a downtrend (75 weeks in) while the P/E sits at the 23rd percentile of its own 2-year range. Underneath, the last four quarters read improving — profit +150.0% year on year, and 17% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Platinum Industries Ltd trades at ₹226, in a downtrend and 75 weeks into that stage. That is −5.5% against its own 200-day average. It sits at 24% of a 52-week range of ₹195 to ₹323. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a downtrend — week 75 of stage 4, confirmed. At ₹226 it trades −5.5% versus its 200-day average and sits at 24% of its 52-week range (₹195–₹323).
Against the market, two honest reads. Cumulative: over the last 2.4 years the stock moved +10% while the NIFTY 500 moved +19% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Platinum Industries Ltd trades at 23.7× P/E, near the bottom of its own range — cheaper only 23% of the time. Its long-run median P/E is 29.4×, measured across 2.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 23.7× is near the bottom of its own range — cheaper only 23% of the time, against a long-run median of 29.4× measured over 2.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +4.3% against a −18.2% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Platinum Industries Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 3 quarters ago at −27.8% and has held its recovery at +150.0% (single-quarter readings), ROCE slipping at 16.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +14.8% | +24.9% | +38.3% | — |
| Profit | +2.0% | +10.3% | +59.1% | — |
| EPS | +4.3% | +0.1% | −27.1% | — |
| Share price | −18.2% | — | — | — |
4-Factor Sector Score
46.8/100 — rank 16 of 27 in Speciality Chemicals · 70% evidence confidence
Platinum Industries Ltd scores 46.8 out of 100 against the 27 companies it is compared with in Speciality Chemicals, ranking 16. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 16.7 + 12.7 + 10.8 + 6.6 = 46.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Platinum Industries Ltd reported ₹132 Cr of revenue in the Mar 26 quarter, +36.1% year on year. That is the 2nd straight quarter of year-on-year growth. Over 5 years it has compounded at 38.3% a year. The last full year, FY26, came in at ₹450 Cr. The last four reported quarters add to ₹450 Cr.
FY26 revenue came in at ₹450 Cr (+14.8% on the year), capping 5 years at 38.3% compound. The latest quarter (Mar 26) printed ₹132 Cr, +36.1% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +14.7% growth against the decade's 38.3% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +14.5% over the last 4 quarters against +30.6%/yr over the last 8 — rolling over; TTM profit +0.0% vs +8.9%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Platinum Industries Ltd's operating margin is 12.0% in the Mar 26 quarter, +4.0 percentage points against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged 9.0% to 23.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 12.0%, +4.0 pp against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged 9.0%–23.0%.
Why the margin moved: operating margin went +3.5 pp year on year while gross margin went +3.9 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Platinum Industries Ltd earned ₹15.0 Cr of net profit in the Mar 26 quarter, +150.0% year on year. Full-year FY26 profit was ₹51.0 Cr. The 5-year compound rate is 59.1%. That is 11.4% of the quarter's revenue. The same quarter a year earlier earned ₹6.0 Cr.
Mar 26 profit was ₹15.0 Cr, +150.0% year on year. On the full year, FY26 printed ₹51.0 Cr (+2.0%), and the 5-year compound rate is 59.1%.
Why profit moved: revenue contributed +36.1% and the margin +4.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +23.9% vs revenue +14.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 17% of Platinum Industries Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−1.0 Cr of operating cash against ₹51.0 Cr of profit. After ₹35.0 Cr of capital spending, ₹−36.0 Cr was left as free cash.
FY26: operating cash of ₹−1.0 Cr against reported profit of ₹51.0 Cr, leaving free cash of ₹−36.0 Cr after ₹35.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 17% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 17%: the cash cycle stretched 96 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 96 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Platinum Industries Ltd's cash conversion cycle runs 95 days in FY26, up from −1 days in FY21. Capital spending ran ₹130 Cr over the last 3 years. At FY26 sales of ₹450 Cr each day of that cycle holds about ₹1.2 Cr, so roughly ₹117 Cr sits inside the business at any moment.
FY26: debtors at 101 days, inventory at 78 days — roughly 2.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 95 days, looser than FY21's −1.
The full loop: cash goes out to suppliers and production on day 0; stock waits 78 days to sell; customers pay about 101 days after that; and suppliers themselves are paid at 83 days — netting out to the 95-day cycle.
In money terms: at FY26 sales of ₹450 Cr, each day of the cycle holds about ₹1.2 Cr — so the 95-day loop keeps roughly ₹117 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹130 Cr over the last 3 fiscal years against ₹13.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹45.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Platinum Industries Ltd earns a ROCE of 16% in FY26. Return on invested capital clears the cost of that capital by +1.7 percentage points, so growth here adds value rather than only size. The wiring behind it is 11.3% net margin on 0.82× asset turns.
FY26 ROCE is 16%.
Why the return is what it is — the wiring (FY26): 11.3% net margin × 0.82× asset turns × 1.24× balance-sheet leverage ≈ 11.5% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 13.7% − 12.0% = a +1.7 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Platinum Industries Ltd carries total debt of ₹10.0 Cr against shareholder equity of ₹455 Cr as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.31 in FY23 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹10.0 Cr against shareholder equity of ₹455 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.31 (FY23) to 0.02 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 3.5 points of Platinum Industries Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 0.3% of the company. Promoters moved −1.0 points over the same window, to 70.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −3.5 points over 8 quarters to 0.3%; Promoters: −1.0 points over 8 quarters to 70.0%; Domestic institutions: +1.0 points over 8 quarters to 3.7%.
🚨 Why the register moved: foreign institutions drove it (−3.5 points), alongside promoters (−1.0 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Platinum Industries Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Sunshield Chemicals Ltd530845 | 70.0/100Favorable setup72% evidence | TURNING | 28.4/35 Revenue 20.5% · PAT 100% · OPM change 5 pp 83% evidence | 16.3/25 ROCE 19.9% · OPM 15% 76% evidence | 11.2/20 P/E 35.1× · PEG — 50% evidence | 14.1/20 RS sector 2.3% · RS bench 22.4% · 1Y 59.8%11 of 11 weeks ahead 70% evidence |
| Exact sum: 28.4 + 16.3 + 11.2 + 14.1 = 70 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Privi Speciality Chemicals LtdPRIVISCL | 64.2/100Mixed-positive evidence75% evidence | LEADER | 24.9/35 Revenue 21.6% · PAT 62.1% · OPM change -1 pp 95% evidence | 17.8/25 ROCE 22.3% · OPM 23% 76% evidence | 9.3/20 P/E 40.4× · PEG — 15% evidence | 12.2/20 RS sector 2.6% · RS bench 19.1% · 1Y 45.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 17.8 + 9.3 + 12.2 = 64.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Pidilite Industries LtdPIDILITIND | 63.6/100Mixed-positive evidence90% evidence | TURNING | 21.8/35 Revenue 11.1% · PAT 17.9% · OPM change 3 pp 88% evidence | 19.6/25 ROCE 31% · OPM 23% 100% evidence | 7.6/20 P/E 66.6× · PEG 3.73 100% evidence | 14.6/20 RS sector 5.2% · RS bench 7.2% · 1Y 11.5%6 of 10 weeks ahead 70% evidence |
| Exact sum: 21.8 + 19.6 + 7.6 + 14.6 = 63.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Vikram Thermo (India) Ltd530477 | 63.1/100Mixed-positive evidence63% evidence | TURNING | 23.1/35 Revenue 7% · PAT 100% · OPM change 7.1 pp 83% evidence | 19.2/25 ROCE 36.4% · OPM 31.7% 76% evidence | 8.9/20 P/E 20× · PEG — 50% evidence | 11.9/20 RS sector — · RS bench 40.3% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 23.1 + 19.2 + 8.9 + 11.9 = 63.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Yasho Industries LtdYASHO | 62.6/100Mixed-positive evidence87% evidence | TURNING | 29.3/35 Revenue 34.1% · PAT 100% · OPM change 7 pp 100% evidence | 8.7/25 ROCE 8.9% · OPM 24% 100% evidence | 12.1/20 P/E 80.7× · PEG 1.15 65% evidence | 12.5/20 RS sector -2.4% · RS bench 109.3% · 1Y 97.1%11 of 11 weeks ahead 70% evidence |
| Exact sum: 29.3 + 8.7 + 12.1 + 12.5 = 62.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Tatva Chintan Pharma Chem LtdTATVA | 61.4/100Mixed-positive evidence93% evidence | BREAKING OUT | 30.7/35 Revenue 41.1% · PAT 100% · OPM change 4 pp 100% evidence | 6.6/25 ROCE 7.1% · OPM 19% 100% evidence | 4.8/20 P/E 79.8× · PEG 5.63 65% evidence | 19.3/20 RS sector 21.3% · RS bench 40.9% · 1Y 56.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 30.7 + 6.6 + 4.8 + 19.3 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Panama Petrochem LtdPANAMAPET | 57.5/100Mixed-positive evidence90% evidence | TURNING | 17.5/35 Revenue 9.7% · PAT 14.5% · OPM change 2 pp 88% evidence | 13.3/25 ROCE 19.2% · OPM 11% 100% evidence | 15.8/20 P/E 12.9× · PEG 0.55 100% evidence | 10.9/20 RS sector -5.8% · RS bench 42.3% · 1Y 31.6%10 of 11 weeks ahead 70% evidence |
| Exact sum: 17.5 + 13.3 + 15.8 + 10.9 = 57.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Kronox Lab Sciences LtdKRONOX | 56.7/100Mixed-positive evidence61% evidence | 13.6/35 Revenue 1% · PAT 8.2% · OPM change 6.8 pp 83% evidence | 21.2/25 ROCE 36% · OPM 36.4% 95% evidence | 11.1/20 P/E 20.3× · PEG — 15% evidence | 10.8/20 RS sector — · RS bench 5.4% · 1Y — 25% evidence | |
| Exact sum: 13.6 + 21.2 + 11.1 + 10.8 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Alkyl Amines Chemicals LtdALKYLAMINE | 56.5/100Mixed-positive evidence73% evidence | TURNING | 20.5/35 Revenue 17.4% · PAT 100% · OPM change -0.1 pp 71% evidence | 18.9/25 ROCE 41.3% · OPM 14.5% 95% evidence | 9.3/20 P/E 48.2× · PEG — 50% evidence | 7.8/20 RS sector -14.6% · RS bench 3% · 1Y -18.7%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.5 + 18.9 + 9.3 + 7.8 = 56.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Aether Industries LtdAETHER | 55.9/100Mixed-positive evidence100% evidence | BREAKING OUT | 24.5/35 Revenue 34.4% · PAT 34.3% · OPM change -1 pp 100% evidence | 10.6/25 ROCE 11.9% · OPM 31% 100% evidence | 4.3/20 P/E 85.2× · PEG 8.9 100% evidence | 16.5/20 RS sector 30.6% · RS bench 51.5% · 1Y 97%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 10.6 + 4.3 + 16.5 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Aarti Industries LtdAARTIIND | 53.7/100Mixed-positive evidence100% evidence | FADING | 27.9/35 Revenue 27% · PAT 100% · OPM change 3 pp 100% evidence | 8.8/25 ROCE 6.8% · OPM 16% 100% evidence | 6.9/20 P/E 34× · PEG 2.05 100% evidence | 10.1/20 RS sector -0.7% · RS bench 15.3% · 1Y 13.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 27.9 + 8.8 + 6.9 + 10.1 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Vinati Organics LtdVINATIORGA | 50.0/100Mixed-positive evidence76% evidence | ASLEEP | 12.2/35 Revenue 5.1% · PAT 5.7% · OPM change -5 pp 95% evidence | 17.4/25 ROCE 19.8% · OPM 24% 76% evidence | 13.3/20 P/E 30.2× · PEG — 50% evidence | 7.1/20 RS sector -4.1% · RS bench -14% · 1Y -30.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.2 + 17.4 + 13.3 + 7.1 = 50 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13DMCC Speciality Chemicals LtdDMCC | 49.4/100Mixed-negative evidence76% evidence | FADING | 20.4/35 Revenue 34.8% · PAT 27% · OPM change -2.1 pp 83% evidence | 11.4/25 ROCE 15.3% · OPM 10% 95% evidence | 10.5/20 P/E 25.8× · PEG — 15% evidence | 7.1/20 RS sector -11.1% · RS bench 2.9% · 1Y -9.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 11.4 + 10.5 + 7.1 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Fineotex Chemical LtdFCL | 47.6/100Mixed-negative evidence94% evidence | TURNING | 18.7/35 Revenue 91.5% · PAT 41% · OPM change -2 pp 100% evidence | 13.0/25 ROCE 18.3% · OPM 16% 100% evidence | 3.3/20 P/E 37.4× · PEG 4.19 100% evidence | 12.6/20 RS sector -2.3% · RS bench 42% · 1Y 45.8%11 of 11 weeks ahead 70% evidence |
| Exact sum: 18.7 + 13 + 3.3 + 12.6 = 47.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Grauer & Weil (India) LtdGRAUWEIL | 46.9/100Mixed-negative evidence96% evidence | TURNING | 15.5/35 Revenue 4.9% · PAT 4.4% · OPM change 8 pp 88% evidence | 16.8/25 ROCE 21.4% · OPM 17% 100% evidence | 7.7/20 P/E 21.2× · PEG 4.01 100% evidence | 6.9/20 RS sector -15% · RS bench -1.6% · 1Y -24.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 16.8 + 7.7 + 6.9 = 46.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Platinum Industries Ltdthis pagePLATIND | 46.8/100Mixed-negative evidence70% evidence | ASLEEP | 16.7/35 Revenue 14.5% · PAT 0% · OPM change 4 pp 83% evidence | 12.7/25 ROCE 15.7% · OPM 12% 95% evidence | 10.8/20 P/E 23.7× · PEG — 15% evidence | 6.6/20 RS sector -10.6% · RS bench -9% · 1Y -23.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 12.7 + 10.8 + 6.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Neogen Chemicals LtdNEOGEN | 44.0/100Mixed-negative evidence90% evidence | LEADER | 15.3/35 Revenue 18.1% · PAT 6.1% · OPM change 2 pp 100% evidence | 6.9/25 ROCE 6.5% · OPM 19% 100% evidence | 5.1/20 P/E 156× · PEG — 50% evidence | 16.7/20 RS sector 15.8% · RS bench 33.3% · 1Y 28.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 6.9 + 5.1 + 16.7 = 44 · Decision use: Price leads the evidence: RS versus the benchmark is 33.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Vishnu Chemicals LtdVISHNU | 43.5/100Mixed-negative evidence100% evidence | FADING | 15.5/35 Revenue 16.5% · PAT 17.2% · OPM change -1 pp 100% evidence | 11.8/25 ROCE 16.3% · OPM 15% 100% evidence | 6.2/20 P/E 27.6× · PEG 2.82 100% evidence | 10.0/20 RS sector -2.3% · RS bench 13.3% · 1Y 23.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 11.8 + 6.2 + 10 = 43.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Anupam Rasayan India LtdANURAS | 41.5/100Mixed-negative evidence78% evidence | ASLEEP | 20.6/35 Revenue 64.5% · PAT 38.8% · OPM change -7 pp 83% evidence | 10.3/25 ROCE 7.4% · OPM 22% 76% evidence | 8.0/20 P/E 80.8× · PEG — 50% evidence | 2.6/20 RS sector -17.4% · RS bench -3.6% · 1Y 5.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 10.3 + 8 + 2.6 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Chemcon Speciality Chemicals LtdCHEMCON | 40.4/100Mixed-negative evidence77% evidence | TURNING | 16.1/35 Revenue 15.7% · PAT -3.5% · OPM change 1.2 pp 83% evidence | 8.8/25 ROCE 6.4% · OPM 11.8% 95% evidence | 11.5/20 P/E 27.2× · PEG — 50% evidence | 4.0/20 RS sector -21.7% · RS bench -12% · 1Y -17.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 16.1 + 8.8 + 11.5 + 4 = 40.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Galaxy Surfactants LtdGALAXYSURF | 40.1/100Mixed-negative evidence90% evidence | TURNING | 12.0/35 Revenue 24.2% · PAT -13.1% · OPM change -2 pp 88% evidence | 12.9/25 ROCE 13.5% · OPM 9% 100% evidence | 8.9/20 P/E 24.8× · PEG 4.39 100% evidence | 6.3/20 RS sector -12.1% · RS bench -4.1% · 1Y -25.1%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12 + 12.9 + 8.9 + 6.3 = 40.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Amines & Plasticizers LtdAMNPLST | 40.0/100Mixed-negative evidence77% evidence | TURNING | 9.4/35 Revenue -13.8% · PAT -14.3% · OPM change 2 pp 83% evidence | 15.2/25 ROCE 16.7% · OPM 15% 95% evidence | 8.5/20 P/E 29.9× · PEG — 50% evidence | 6.9/20 RS sector -19.4% · RS bench 3.8% · 1Y -12.3%10 of 10 weeks ahead 70% evidence |
| Exact sum: 9.4 + 15.2 + 8.5 + 6.9 = 40 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Transpek Industry LtdTRANSPEK | 38.4/100Mixed-negative evidence77% evidence | TURNING | 8.1/35 Revenue -4.4% · PAT -6.3% · OPM change -7.5 pp 83% evidence | 9.1/25 ROCE 8.3% · OPM 12% 95% evidence | 13.8/20 P/E 16.2× · PEG — 50% evidence | 7.4/20 RS sector -19.7% · RS bench 8% · 1Y -19.4%3 of 10 weeks ahead 70% evidence |
| Exact sum: 8.1 + 9.1 + 13.8 + 7.4 = 38.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24Paushak LtdPAUSHAKLTD | 36.2/100Mixed-negative evidence81% evidence | TURNING | 11.5/35 Revenue 15.4% · PAT -15.7% · OPM change -1 pp 95% evidence | 9.9/25 ROCE 8.3% · OPM 31% 95% evidence | 8.3/20 P/E 36.6× · PEG — 50% evidence | 6.5/20 RS sector -27.5% · RS bench 7.3% · 1Y -3.2%6 of 11 weeks ahead 70% evidence |
| Exact sum: 11.5 + 9.9 + 8.3 + 6.5 = 36.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Clean Science & Technology LtdCLEAN | 34.1/100Adverse evidence94% evidence | ASLEEP | 4.4/35 Revenue -0.4% · PAT -13.8% · OPM change -5 pp 100% evidence | 17.6/25 ROCE 20.6% · OPM 36% 100% evidence | 8.6/20 P/E 33.5× · PEG 6.24 100% evidence | 3.5/20 RS sector -24.4% · RS bench -18% · 1Y -40.9%2 of 10 weeks ahead 70% evidence |
| Exact sum: 4.4 + 17.6 + 8.6 + 3.5 = 34.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Thirumalai Chemicals LtdTIRUMALCHM | 24.8/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue -15.4% · PAT -80% · OPM change -1.4 pp 62% evidence | 0.9/25 ROCE -3.1% · OPM 1.4% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.8/20 RS sector -15.9% · RS bench -22.9% · 1Y -40.9%1 of 10 weeks ahead 70% evidence |
| Exact sum: 9.1 + 0.9 + 10 + 4.8 = 24.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Amal LtdAMAL | 50.0/100Thin evidence · provisional50% evidence | 19.8/35 Revenue 72.5% · PAT 19.1% · OPM change -31.6 pp 53% evidence | 15.1/25 ROCE 36.3% · OPM 12.9% 57% evidence | 10.9/20 P/E 23× · PEG — 15% evidence | 4.2/20 RS sector -18.2% · RS bench -26.3% · 1Y -51.4%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 19.8 + 15.1 + 10.9 + 4.2 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Platinum Industries Ltd's share price today?
Platinum Industries Ltd trades at ₹226, −18.2% over the past year. The company is valued at ₹1,241 Cr. The stock sits at 24% of its 52-week range of ₹195–₹323, −5.5% versus its 200-day average. On the tape, the price is in a downtrend, 75 weeks in. — as of 31 July 2026.
What were Platinum Industries Ltd's latest quarterly results?
Platinum Industries Ltd reported revenue of ₹132 Cr and net profit of ₹15.0 Cr for the Mar 26 quarter. Revenue rose 36.1% and profit rose 150.0% year on year. Earnings per share were ₹2.75. The operating margin was 12.0%, 4.0 pp higher than a year earlier. — as of 31 July 2026.
What is Platinum Industries Ltd's revenue?
Platinum Industries Ltd reported revenue of ₹132 Cr in the Mar 26 quarter, +36.1% year on year. For the full FY26 fiscal year, revenue was ₹450 Cr (+14.8%). Over the last 5 years revenue compounded at 38.3% a year. — as of 31 July 2026.
What is Platinum Industries Ltd's profit?
Platinum Industries Ltd earned ₹15.0 Cr of net profit in the Mar 26 quarter, +150.0% year on year. Full-year FY26 profit was ₹51.0 Cr. The operating margin ran 12.0% in the latest quarter. — as of 31 July 2026.
What is Platinum Industries Ltd's market cap?
Platinum Industries Ltd's market capitalisation is ₹1,241 Cr at a share price of ₹226. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Platinum Industries Ltd's P/E ratio?
Platinum Industries Ltd trades at a P/E of 23.7×, at the 23rd percentile of its own 2-year range, against a long-run median of 29.4×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Platinum Industries Ltd pay a dividend?
No — Platinum Industries Ltd has recorded a dividend payout of 0% of profit in each of its last 6 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is Platinum Industries Ltd overvalued?
On its own history, Platinum Industries Ltd looks cheap against its own history: its P/E of 23.7× has been cheaper only 23% of the time in 2 years (long-run median 29.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Platinum Industries Ltd growing?
Yes — Platinum Industries Ltd is growing: latest-quarter revenue +36.1% year on year, profit +150.0%, and the margin +4.0 pp at 12.0%. The 5-year compound rates are 38.3% (revenue) and 59.1% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Platinum Industries Ltd performing?
Platinum Industries Ltd is in a downtrend, 75 weeks in. Its latest quarter's revenue rose 36.1% and profit rose 150.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Platinum Industries Ltd in?
Improving — profit growth bottomed 3 quarters ago at −27.8% and has held its recovery at +150.0% (single-quarter readings), ROCE slipping at 16.0%. The read comes from the last 12 quarters of growth (revenue growth +36.1% latest, profit growth +150.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Platinum Industries Ltd in an uptrend?
No — the price is in a downtrend (week 75 of stage 4), trading −5.5% versus its 200-day average and at 24% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Platinum Industries Ltd beating the market?
Not lately — on a trailing-13-week view Platinum Industries Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-07-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.4 years the stock moved +10% against the NIFTY 500's +19% — behind the index over the full window. — as of 31 July 2026.
Will Platinum Industries Ltd's share price go up?
This page publishes no price forecast for Platinum Industries Ltd. What it measures instead: the share price is ₹226, the price is in a downtrend 75 weeks in. Its P/E of 23.7× sits at the 23rd percentile of its own 2-year range. — as of 31 July 2026.
Who owns Platinum Industries Ltd?
Promoters hold 70.0% of Platinum Industries Ltd, foreign institutions 0.3%, domestic institutions 3.7% and the public 26.0% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 3.5 points over 8 quarters. — as of 31 July 2026.
Does Platinum Industries Ltd have too much debt?
No — Platinum Industries Ltd's debt-to-equity is 0.02, and operating profit covers the interest bill 20×. FY26 borrowings were ₹10.0 Cr against equity of ₹443 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Platinum Industries Ltd's capex?
Platinum Industries Ltd spent ₹130 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹35.0 Cr, with ₹45.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Platinum Industries Ltd's cash flow?
Platinum Industries Ltd generated ₹−1.0 Cr of operating cash flow in FY26 and ₹−36.0 Cr of free cash flow after ₹35.0 Cr of capital spending. Reported profit that year was ₹51.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Platinum Industries Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 17% of Platinum Industries Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−1.0 Cr against reported profit of ₹51.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 31 July 2026.
Where is Platinum Industries Ltd in its business cycle?
Platinum Industries Ltd's FY26 operating margin was 13.0%, against a 6-year band of 9.0%–23.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 12.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Platinum Industries Ltd story?
The sharpest disagreement: profits are rising, but only 17% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Platinum Industries Ltd a stock worth studying right now?
This is not investment advice. The machine read: Platinum Industries Ltd's earnings have outrun its stock. EPS grew +4.3% in a year against a −18.2% price move. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.